Skip to main content
. 2016 Mar 24;5:364. doi: 10.1186/s40064-016-2009-8

Table 6.

VDR polymorphims sub grouping in PCa cases according to clinical parameters

Polymorphisms PSA N (%) Gleason N (%) TNM N (%)
Genotypes <10 ng/mL ≥10 ng/mL Odds (95 % CI) P <7 ≥7 Odds (95 % CI) P T1-T2 T3 Odds (95 % CI) P
FokI
CC 21 (21.88) 16 (16.67) 1.00 26 (24.53) 18 (16.98) 1.00 16 (22.22) 16 (22.22) 1.00
CT 25 (26.04) 24 (25.00) 0.79 (0.34–1.87) 0.76 27 (25.47) 21 (19.81) 0.89 (0.39–2.04) 0.95 24 (33.33) 8 (11.11) 3.00 (1.04–8.65) 0.07
TT 7 (7.29) 3 (3.13) 1.78 (0.40–7.97) 0.69 7 (6.60) 7 (6.60) 0.69 (0.21–2.32) 0.77 5 (6.94) 3 (4.17) 1.67 (0.34–8.18) 0.81
BsmI
AA 2 (2.08) 9 (9.38) 1.00 8 (7.55) 4 (3.77) 1.00 8 (11.11) 2 (2.78) 1.00
AG 23 (23.96) 20 (20.83) 5.18 (1.00–26.82) 0.08 25 (23.58) 21 (19.81) 0.60 (0.16–2.26) 0.66 16 (22.22) 11 (15.28) 0.36 (0.07–2.05) 0.43
GG 28 (29.17) 14 (14.58) 9.00 (1.71–47.39) 0.01* 27 (25.47) 21 (19.81) 0.64 (0.17–2.43) 0.74 21 (29.17) 14 (19.44) 0.38 (0.07–2.03) 0.43
Genotypes in pairs
BsmI - ApaI
AATT 2 (2.11) 9 (9.47) 1.00 8 (8.25) 4 (4.12) 1.00 8 (12.70) 2 (3.17) 1.00
AGTT 10 (10.53) 7 (7.37) 6.43 (1.05–39.33) 0.08 9 (9.28) 6 (6.19) 0.75 (0.15–3.65) 0.97 7 (11.11) 4 (6.35) 0.44 (ND) 0.73
GGGT 9 (9.47) 5 (5.26) 8.10 (1.23–53.20) 0.06 4 (4.12) 6 (6.19) 0.33 (0.06–1.91) 0.41 4 (6.35) 4 (6.35) 0.25 (ND) 0.40
AGGT 12 (12.63) 13 (13.68) 4.15 (0.74–23.23) 0.19 15 (15.46) 15 (15.46) 0.50 (0.12–2.02) 0.52 9 (14.29) 6 (9.52) 0.38 (0.06–2.41) 0.54
GGGG 13 (13.68) 6 (6.32) 9.75 (1.59–59.70) 0.02* 12 (12.37) 7 (7.22) 0.86 (0.19–3.92) 0.85 7 (11.11) 4 (6.35) 0.44 (ND) 0.73
GGTT 6 (6.32) 3 (3.16) 9.00 (ND) 0.08 4 (4.12) 6 (6.19) 0.33 (0.06–1.91) 0.41 4 (6.35) 4 (6.35) 0.25 (ND) 0.40
Dominant model
BsmI
AA + AG 25 (26.04) 29 (30.21) 1.00 33 (31.43) 25 (23.81) 1.00 24 (33.33) 13 (18.06) 1.00
GG 28 (29.17) 14 (14.58) 2.32 (1.01–5.35) 0.07 26 (24.76) 21 (20.00) 0.94 (0.43–2.04) 0.97 21 (29.17) 14 (19.44) 0.81 (0.31–2.11) 0.86
Recessive model
FokI
CC 21 (21.88) 16 (16.67) 1.00 25 (23.81) 18 (17.14) 1.00 16 (22.22) 16 (22.22) 1.00
CT + TT 32 (33.33) 27 (28.13) 0.90 (0.40–2.07) 0.98 34 (32.38) 28 (26.67) 0.87 (0.40–1.92) 0.89 29 (40.28) 11 (15.28) 2.64 (0.99–7.03) 0.09
TaqI
TT 29 (30.21) 15 (15.63) 1.00 27 (25.71) 22 (20.95) 1.00 21 (29.17) 17 (23.61) 1.00
TC + CC 24 (25.00) 28 (29.17) 0.44 (0.19–1.02) 0.08 32 (30.48) 24 (22.86) 1.09 (0.50–2.35) 0.99 24 (33.33) 10 (13.89) 1.94 (0.73–5.16) 0.27
BsmI
AA 2 (2.08) 9 (9.38) 1.00 8 (7.62) 4 (3.81) 1.00 8 (11.11) 2 (2.78) 1.00
AG + GG 51 (53.13) 34 (35.42) 6.75 (1.37–33.18) 0.02* 51 (48.57) 42 (40.00) 0.61 (0.17–2.16) 0.64 37 (51.39) 25 (34.72) 0.37 (0.07–1.89) 0.38

ND no data, CI confidence interval

* Significant data